Studies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine

Show simplified metadata
dc.contributor.authorHaubrich, Richard H.
dc.contributor.authorTakeda, Akira
dc.contributor.authorKoff, Wayne
dc.contributor.authorSmith, Gail
dc.contributor.authorEnnis, Francis A.
dc.contributor.departmentDepartment of Medicine, Division of Infectious Diseases and Immunology
dc.contributor.departmentCenter for Infectious Disease and Vaccine Research
dc.date2022-08-11T08:09:10.000
dc.date.accessioned2022-08-23T16:19:44Z
dc.date.available2022-08-23T16:19:44Z
dc.date.issued1992-03-01
dc.date.submitted2017-11-17
dc.description.abstractSubneutralizing concentrations of sera from human immunodeficiency virus (HIV)-1-infected patients augment HIV infection mediated by Fc receptor uptake by human monocytes and the monocytic cell line U937. Antibody-dependent enhancement (ADE) and neutralization activity were studied in the sera of HIV-1 antibody-negative volunteers who had been immunized with three 40-micrograms doses of a recombinant gp160 (rgp160) candidate HIV vaccine. Volunteers were vaccinated with rgp160 or a hepatitis B vaccine as a control on days 0, 30, and 180. Sera were obtained before and after three doses of vaccine and were tested for ADE and neutralization activity. Serum samples collected before vaccination showed neither neutralization nor ADE activity. Thirteen sera from volunteers who received gp160 and four from placebo recipients failed to show ADE. Three sera showed low levels of neutralization of strain IIIB of HIV. Vaccination with this dose of rgp160 produced neutralizing antibodies in some subjects but did not induce detectable enhancing antibodies.
dc.identifier.citationJ Infect Dis. 1992 Mar;165(3):545-8.
dc.identifier.contextkey11069616
dc.identifier.issn0022-1899 (Linking)
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/infdis_pp/327
dc.identifier.pmid1538159
dc.identifier.submissionpathinfdis_pp/327
dc.identifier.urihttps://hdl.handle.net/20.500.14038/35118
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=1538159&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.jstor.org/stable/30112061
dc.source.issue3
dc.source.journaltitleThe Journal of infectious diseases
dc.source.pages545-8
dc.source.volume165
dc.subjectImmunity
dc.subjectImmunology and Infectious Disease
dc.subjectImmunology of Infectious Disease
dc.subjectInfectious Disease
dc.subjectVirology
dc.titleStudies of antibody-dependent enhancement of human immunodeficiency virus (HIV) type 1 infection mediated by Fc receptors using sera from recipients of a recombinant gp160 experimental HIV-1 vaccine
dc.typeJournal Article
dspace.entity.typePublication
html.description.abstract<p>Subneutralizing concentrations of sera from human immunodeficiency virus (HIV)-1-infected patients augment HIV infection mediated by Fc receptor uptake by human monocytes and the monocytic cell line U937. Antibody-dependent enhancement (ADE) and neutralization activity were studied in the sera of HIV-1 antibody-negative volunteers who had been immunized with three 40-micrograms doses of a recombinant gp160 (rgp160) candidate HIV vaccine. Volunteers were vaccinated with rgp160 or a hepatitis B vaccine as a control on days 0, 30, and 180. Sera were obtained before and after three doses of vaccine and were tested for ADE and neutralization activity. Serum samples collected before vaccination showed neither neutralization nor ADE activity. Thirteen sera from volunteers who received gp160 and four from placebo recipients failed to show ADE. Three sera showed low levels of neutralization of strain IIIB of HIV. Vaccination with this dose of rgp160 produced neutralizing antibodies in some subjects but did not induce detectable enhancing antibodies.</p>
Files
Collections
UMass Chan Faculty and Researcher Publications